Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CNBX PharmaceuticalsCNBX +33.33% Shareholder Yield % is 60.79% as of May. 2026. The stock has 3 warning signs investors should review. Among 1,284 Biotechnology companies, CNBX Pharmaceuticals ranks better than 98.75% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, CNBX Pharmaceuticals's Shareholder Yield % was 60.79%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
CNBX Pharmaceuticals Shareholder Yield % Related Terms
CNBX Pharmaceuticals Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for CNBX Pharmaceuticals's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNBX vs SIGY, LIPO, CARM: Shareholder Yield % Comparison
For the Biotechnology subindustry, CNBX Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CNBX Pharmaceuticals Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where CNBX Pharmaceuticals's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
CNBX Pharmaceuticals (CNBX) has a Shareholder Yield % of 60.79% as of May. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on CNBX Pharmaceuticals and its competitors. According to the industry distribution chart, CNBX Pharmaceuticals ranks #16 out of 1284 companies in the Biotechnology industry, placing it in the top 1.2%.
Is CNBX Pharmaceuticals' Shareholder Yield % too high?
CNBX Pharmaceuticals' current Shareholder Yield % is 60.79%. Based on the distribution chart, CNBX Pharmaceuticals ranks #16 out of 1284 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CNBX Pharmaceuticals' Shareholder Yield % compare to SIGY and LIPO?
According to the Biotechnology industry distribution chart, CNBX Pharmaceuticals ranks #16 out of 1284 companies for Shareholder Yield %. This places CNBX Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on CNBX Pharmaceuticals and its competitors. CNBX Pharmaceuticals's current Shareholder Yield % is 60.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current Shareholder Yield % of 60.79%. The current Shareholder Yield % is 60.79%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current Shareholder Yield % is 60.79% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNBX has been successfully added to your 
